First case report of lorlatinib in the treatment of ALK-fusion-positive lung adenocarcinoma with ovarian metastasis: Clinicopathological and molecular characterization
This case underscores the importance of molecular profiling in diagnosing metastatic tumors and confirms lorlatinib as a highly effective first-line therapy for ALK-positive non-small cell lung cancer with atypical metastases.
Authors
- Shiyu Hua
- Keding Shao (ORCID: https://orcid.org/0000-0002-6578-1149)
- Tianxiang Xu (ORCID: https://orcid.org/0000-0003-0759-6866)
- Xinyi Qiu (ORCID: https://orcid.org/0000-0003-0895-7977)
- Mengqi Wu (ORCID: https://orcid.org/0000-0001-9403-1745)
- Jingying Wang (ORCID: https://orcid.org/0000-0002-9766-2769)
- Yu Zhang (ORCID: https://orcid.org/0000-0002-5430-6772)
- J W Wang (ORCID: https://orcid.org/0000-0002-2633-4450)
- Jiamin Hong
Institutions
- Zhejiang Chinese Medical University (CN)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1097/md.0000000000045222
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00